FindTrial
Sign In

E7090

DRUG5 trials

Sponsors

Eisai Co., Ltd., National Cancer Center, Japan

Conditions

Advanced or Recurrent Solid TumorsBreast NeoplasmsCholangiocarcinomaFGFR Gene AlterationsHealthy ParticipantsTumors

Phase 1

Phase 1 Study of E7090 in Subjects With Solid Tumor
CompletedNCT02275910
Eisai Co., Ltd.Tumors
Start: 2014-10-28End: 2021-09-03Updated: 2025-12-16
A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants
CompletedNCT04565574
Eisai Co., Ltd.Healthy Participants
Start: 2020-10-16End: 2021-03-31Updated: 2021-11-01
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
Active, not recruitingNCT04572295
Eisai Co., Ltd.Breast Neoplasms
Start: 2020-10-09End: 2027-03-31Target: 51Updated: 2026-03-11

Phase 2

A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
CompletedNCT04238715
Eisai Co., Ltd.Cholangiocarcinoma
Start: 2020-01-22End: 2025-11-03Updated: 2026-03-02
NCCH2006/MK010 Trial (FORTUNE Trial)
RecruitingNCT04962867
National Cancer Center, JapanAdvanced or Recurrent Solid Tumors, FGFR Gene Alterations
Start: 2021-06-15End: 2028-03-31Target: 75Updated: 2025-10-03

Related Papers

Tasurgratinib (E7090) for cholangiocarcinoma with fibroblast growth factor receptor 2 fusions/rearrangements: a multicenter, open-label, Phase 2 study.
2025-11-01
Abstract P4-10-18: Potential predictive biomarkers for a fibroblast growth factor receptor (FGFR) inhibitor: Phase 1b trial of tasurgratinib (E7090) with endocrine therapies (ET) for ER+, HER2+ recurrent/metastatic breast cancer (BC) resistant to CDK4/6 inhibitors
Clinical Cancer Research2025-06-13
A phase II basket trial evaluating the efficacy of tasurgratinib (E7090) in patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE study.
Journal of Clinical Oncology2025-05-28
Phase Ib trial of tasurgratinib (E7090) with or without endocrine therapies for patients (pts) with ER+, HER2− recurrent/metastatic breast cancer (BC) after receiving a CDK4/6 inhibitor.
Journal of Clinical Oncology2024-06-012 citations
Pivotal single-arm, phase 2 trial of tasurgratinib for patients with fibroblast growth factor receptor (FGFR)-2 gene fusion-positive cholangiocarcinoma (CCA).
Journal of Clinical Oncology2024-01-2013 citations
Genomic characterization between <scp>HER2</scp>‐positive and negative gastric cancer patients in a prospective trial
Cancer Medicine2023-06-1612 citations
A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial.
2022-08-094 citations
ACT-1 Multicenter investigator-initiated registration-directed Phase 2 study of E7090 in subjects with advanced or recurrent solid tumors with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial
Neuro-Oncology Advances2021-12-01
SYST-01. MULTICENTER INVESTIGATOR-INITIATED PHASE 2 STUDY OF E7090 IN SUBJECTS WITH ADVANCED OR RECURRENT SOLID TUMORS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) GENE ALTERATION: FORTUNE STUDY
Neuro-Oncology Advances2021-09-21
Abstract 1414: Effect of E7090, an FGFR1-3 selective inhibitor, on resistance to a CDK4/6 inhibitor and endocrine therapy in ER(+)/HER2(-) breast cancer preclinical models
Cancer Research2021-07-013 citations
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements
Future Oncology2020-07-17158 citations
Abstract B160: First-in-human phase 1 study of E7090, a novel selective inhibitor of FGFRs, in patients with advanced solid tumors
Molecular Cancer Therapeutics2018-01-011 citations
Abstract 2095: E7090, a novel and selective FGFR inhibitor, for the treatment of cholangiocarcinoma cells harboring FGFR2-fusion genes
Cancer Research2017-07-013 citations
Abstract 3778: In vitro and in vivo characterization of E7090, a novel and selective FGFR inhibitor, for the treatment of endometrial cancer
Cancer Research2016-07-15